Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.
Eye. 2008 Apr 18
Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen((R))) in refractory pseudophakic cystoid macular oedema (CME).
Design and methods
Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT).
Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT showed improvement of the retinal thickness in the macular area.
Intravitreal pegaptanib sodium (Macugen((R))) is a promising treatment for pseudophakic cystoid macular oedema resistant to other medical treatment strategies. However, further study is needed to assess the treatment's long term efficacy and the need for retreatment.Eye advance online publication, 18 April 2008; doi:10.1038/eye.2008.2.